Reports Q4 revenue $1.33M, consensus $859,700. “We remain on track to report top-line data in 2H’25 from our Phase 2 clinical trial of DNTH103 ...

Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) has received a consensus recommendation of “Buy” from the nine ...

Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H’25Phase 3 CAPTIVATE trial of ...

Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.71 per share a year ago. These ...

Dianthus Therapeutics, a clinical-stage biotechnology company, has appointed John C. King as Chief Commercial Officer, bringing over 25 years of experience in the biotechnology industry ...

TD Cowen initiated coverage of Dianthus (DNTH) with a Buy rating and no price target The firm says DNTH103 is “highly potent” and selectively targets classical pathway while preserving lectin ...

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies.

When plants come up, they can be grown under fluorescent lights or next to a sunny window until frost is done for the season (similar to annual flowers). They then should be gradually acclimated to ...

Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, ...

NEW YORK and WALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of ...

NEW YORK - Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a pharmaceutical company based in New York with a market capitalization of $588 million, has announced the departure of Tomas Kiselak from its ...

Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) has earned a consensus rating of “Buy” from the nine analysts that are currently covering the firm, Marketbeat reports.